依达拉奉右莰醇注射液治疗急性脑梗死的临床观察  

Clinical Observation of Edaravone and Dexborneol Concentrated Solution for Injection on Treatment of Acute Cerebral Infarction

作　　者：王辉[1] WANG Hui(Department of Neurology,Nanyang Central Hospital,Nanyang Henan 473000,China)

机构地区：[1]南阳市中心医院神经内科四病区,河南南阳473000

出　　处：《临床研究》2022年第10期85-88,共4页Clinical Research

摘　　要：目的研究依达拉奉右莰醇运用于急性脑梗死中的价值。方法选择南阳市中心医院2019年12月至2021年12月接收的88例急性脑梗死患者,以随机数字表法划分成两组,各44例。研究组选择依达拉奉右莰醇,对照组使用依达拉奉,比较两组用药结果。结果研究组治疗有效率(90.91%)高于对照组(70.45%),差异有统计学意义(P<0.05)。用药前两组、炎性因子改良Rankin(MRS评分)、神经功能缺损(NIHSS评分)、氧化应激、不良反应发生率、脑血流动力学指标异常率、颈动脉超声指标比较,差异无统计学意义(P>0.05)。用药后研究组各指标均优于对照组,差异有统计学意义(P<0.05)。结论依达拉奉右莰醇运用于急性脑梗死中效果更为显著,能够消除炎性反应,促进氧化应激反应及神经功能改善。Objective To study the clinical value of edaravone and dexborneol on treatment of acute cerebral infarction.Methods A total of 88 acute cerebral infarction patients treated in Nanyang Central Hospital from December 2019 to December 2021 were selected.According to random number table,patients were divided into study group(N=44,edaravone and dexborneol)and control group(N=44,edaravone),the results of two groups were compared.Results The total effective rate of the study group was 90.91%,higher than that of the control group(70.45%)(P<0.05).There were no significant differences between the two groups in terms of improved Rankin(MRS),neurological deficit(NIHSS),oxidative stress,the incidence of adverse reactions,abnormal rate of cerebral hemodynamic indexes and carotid ultrasound indexes before administration(P>0.05).After administration,all indexes in the study group were better than those in the control group(P<0.05).Conclusion Edaravone and dexborneol has significant effect which can effectively reduce the inflammatory response,improve the oxidative stress reaction,neurological function.

关 键 词：急性脑梗死 依达拉奉右莰醇 神经功能 依达拉奉 

分 类 号：R743.33[医药卫生—神经病学与精神病学]